General Information of DTT (ID: TTZOVE0)

DTT Name Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DTT Info
Gene Name SCN5A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
14 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benzonatate DM9U4FO Cough MD12 Approved [1]
Dibucaine DMF9G7L Anaesthesia 9A78.6 Approved [2]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [3]
Dyclonine DMU6OFP Pain MG30-MG3Z Approved [4]
Ethotoin DMXWOCP Complex partial seizure 8A68.0 Approved [1]
Fosphenytoin DMOX3LB Epilepsy 8A60-8A68 Approved [5]
Hexylcaine DMEADRK Anaesthesia 9A78.6 Approved [1]
Indecainide DMUV8OR Dysrhythmias BC9Z Approved [6]
LOMERIZINE DME0TC8 Migraine 8A80 Approved [7]
Mephenytoin DM5UGDK Epilepsy 8A60-8A68 Approved [5]
Mexiletine DMCTE9R Ventricular tachycardia BC71 Approved [3]
Moricizine DMOMBJW Arrhythmia BC9Z Approved [8]
Prilocaine DMI7DZ2 Pain MG30-MG3Z Approved [4]
Tetrodotoxin DMWMPRG Bacterial infection 1A00-1C4Z Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Approved Drug(s)
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
F-15845 DMAH12E Angina pectoris BA40 Phase 1 [9]
------------------------------------------------------------------------------------
4 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aryl carboxamide derivative 1 DMTZRCW N. A. N. A. Patented [10]
Aryl carboxamide derivative 2 DM146TA N. A. N. A. Patented [10]
Aryl carboxamide derivative 3 DM6FQ8L N. A. N. A. Patented [10]
Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 DMUNFAT N. A. N. A. Patented [10]
------------------------------------------------------------------------------------
5 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Encainide DMK0GHV Heart arrhythmia BC65 Withdrawn from market [8]
LUBELUZOLE DMFGMD9 Neurological disorder 6B60 Discontinued in Preregistration [7]
Acecainide DMKM543 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 3 [4]
SIPATRIGINE DMMQ4GC Neurological disorder 6B60 Discontinued in Phase 2 [7]
PD-85639 DMNUKB4 N. A. N. A. Terminated [7]
------------------------------------------------------------------------------------
7 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
1-[5-(4-Chlorophenyl)-2-furoyl]piperazine DM8NMAV Discovery agent N.A. Investigative [11]
aconitine DMFOZ60 Discovery agent N.A. Investigative [12]
batrachotoxin DMYH9SU Discovery agent N.A. Investigative [13]
KC-12291 DMY6QOR Discovery agent N.A. Investigative [14]
N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine DMCZD37 Discovery agent N.A. Investigative [15]
N-Butyl-N'-(4-methyl-benzoyl)-guanidine DM8U70E Discovery agent N.A. Investigative [15]
veratridine DMUF8JZ Discovery agent N.A. Investigative [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Investigative Drug(s)
Molecule Interaction Atlas

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
3 Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
4 Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
5 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
6 Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21.
7 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
8 From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
9 Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91.
10 Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
11 Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86.
12 Properties of aconitine-modified sodium channels in single cells of mouse ventricular myocardium. Gen Physiol Biophys. 1986 Oct;5(5):473-84.
13 Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol Pharmacol. 1986 Dec;30(6):617-23.
14 Sodium late current blockers in ischemia reperfusion: is the bullet magic J Med Chem. 2008 Jul 10;51(13):3856-66.
15 Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers. Bioorg Med Chem Lett. 2001 Dec 17;11(24):3151-5.
16 Sodium channel comodification with full activator reveals veratridine reaction dynamics. Mol Pharmacol. 1990 Feb;37(2):144-8.